MORC3 and cancer: Finally, in 2017, Albayda reported an increased risk for cancer in a cohort of 56 NXP2+ DM patients compared with the general population (3.68-fold increased risk), whereas no differences were found between NXP2+ and NXP2− IIM cases [13].